Starting eculizumab as rescue therapy in refractory myasthenic crisis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s10072-023-06900-y.pdf
Reference10 articles.
1. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30
2. Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897–910
3. Roper J, Fleming ME, Long B, Koyfman A (2017) Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med 53:843–853
4. Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R, REGAIN Study Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986
5. Monteleone J, Gao X, Kleijn HJ et al (2021) Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Front Neurol 12:696385. https://doi.org/10.3389/fneur.2021.696385 eCollection 2021
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients;Journal of Neurology;2024-07-30
2. Autoimmune Neuromuscular Disorders: Emerging Insights and Future Frontiers;Brain Sciences;2024-03-12
3. Ravulizumab in myasthenic crisis: the first case report;Journal of Neurology;2024-02-23
4. Eculizumab as Additional Rescue Therapy in Myasthenic Crisis;Muscles;2024-02-07
5. Novel uses of complement inhibitors in myasthenia gravis—Two case reports;Muscle & Nerve;2024-01-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3